ACO1 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat T lymphocyte line, engineered for disruption of the ACO1 gene. This loss-of-function model enables targeted investigation of iron regulatory protein 1 (IRP1) functions in a human immune cell context. The polyclonal format provides a genetically heterogeneous population of null alleles, suitable for studying gene function without clonal selection artifacts.
The Jurkat cell line is an immortalized human T lymphocyte line originating from a patient with acute T cell leukemia. Widely employed as a model system for T cell signaling, activation, and apoptosis, Jurkat cells enable robust interrogation of pathways underlying adaptive immunity. Their rapid growth and ease of manipulation make them a preferred chassis for CRISPR-based gene editing, facilitating high-throughput functional genomics and biochemical analyses.
ACO1 encodes IRP1, a bifunctional protein that switches between metabolic and regulatory roles depending on iron availability. In iron-replete cells, IRP1 incorporates a [4Fe-4S] cluster and acts as cytosolic aconitase, driving TCA cycle flux. Under iron scarcity, cluster loss exposes its IRE-binding domain, enabling IRP1 to interact with IREs in mRNAs encoding TFRC, ferritin (FTH1/FTL), ferroportin (SLC40A1), and DMT1 (SLC11A2). This leads to TFRC mRNA stabilization and translational repression of iron storage/export proteins, thereby optimizing iron uptake and utilization. Regulatory inputs include intracellular iron concentration, ROS, NO, and hypoxia, ensuring tight coordination with cellular redox status. IRP1 functions downstream of the E3 ubiquitin ligase FBXL5, which targets IRPs for degradation in high iron, and interacts with the translation initiation complex eIF4F at IREs. Its activity is balanced with IRP2 to maintain iron homeostasis across cell types.
In T lymphocytes, iron availability influences proliferation, differentiation, and effector functions, linking ACO1-mediated iron regulation to adaptive immunity. IRP1 dysregulation has been implicated in T cell malignancies and altered immune responses. Jurkat cells, with their leukemic origin, provide a unique backdrop to dissect how iron-sensing pathways intersect with oncogenic signaling and metabolic reprogramming. This knockout model allows dissection of IRP1??s role in mitochondrial metabolism, TCA cycle flux, and redox balance, parameters critical for T cell activation and survival. Moreover, Jurkat ACO1 knockout cells serve as a platform to explore iron-dependent cell death pathways such as ferroptosis, which is increasingly recognized in cancer immunotherapy contexts.
Researchers can apply this model in functional studies measuring TFRC surface expression via flow cytometry, ferritin levels by Western blot, and intracellular labile iron pool with calcein-AM. Aconitase enzymatic activity assays and Seahorse metabolic flux analyses directly evaluate IRP1??s metabolic roles. RT-qPCR assessment of IRE-containing targets (TFRC, FTH1, FTL, SLC11A2) validates post-transcriptional regulation. Additional applications include oxidative stress challenge with ROS detection probes, viability assays under iron chelation, and co-culture systems to assess immune function. Combined with pharmacological modulators of iron homeostasis, these polyclonal knockout cells facilitate high-content screening for iron metabolism modulators in T cell biology and cancer. For further inquiries or technical support, please contact Ascent Research.
